3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
9
Prostatic Neoplasms
4
Neoplasms
3
Uveal Melanoma
2
Stomach Neoplasms
1
Renal Insufficiency, Chronic
1
Oligodendroglioma
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Glioma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bile Duct Neoplasms
1
Astrocytoma
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
Protein Subunit Vaccines
×
Clear all
NCT02429440
2017-08-17
UroRCC
University Hospital Tuebingen
Phase 1/2
Unknown
40 enrolled